Trial Profile
A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Effect on Biomarkers of AZD3293 Including an Open-Label Food Effect Group in Healthy Male and Non-Fertile Female Volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 09 Oct 2015
Price :
$35
*
At a glance
- Drugs Lanabecestat (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions; Pharmacodynamics
- 08 Jan 2013 New trial record
- 01 Dec 2012 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.